Research Interests
Systems biology; functional genomics and proteomics; discovery and characterization of individual genes; understanding the impact of thousands of mutations found in patient samples; translation of the cancer genome to the clinic as precision medicine; development of approaches for the identification of rational combination therapies designed to intercept adaptive responses induced by targeted therapy; implementation of a high-throughput, cost-effective functional proteomics platform; novel trials platform targeting adaptation to therapy.
Current Affiliations
Director, precision oncology, director, SMMART trials, and Wayne and Julie Drinkward Endowed Chair, precision oncology, professor, oncological services, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
Previous Positions
Section chief, precision systems oncology division of oncological sciences (2021-2024), associate director, clinical research ad interim (2019-2021), professor, cell, developmental, and cancer biology (2018-2021), Oregon Health and Science University, Portland, Oregon; co-director, Institute of Personalized Cancer Therapy (2010-2018), chairman, systems biology (2006-2018), director, Kleberg Center for Molecular Markers (2004-2018), chairman, molecular therapies (2001-2006), professor, breast medical oncology (2000-2018), professor, immunology (1995-2018), professor, medicine (1994-2008), associate head, medicine (19998-2000), codirector, clinical genetics research program (1996-1997), medical director, clinical cancer genetics research program (1996-2001), chief, molecular therapies (1994-2008), The University of Texas, MD Anderson Cancer Center, Houston, Texas; director, oncology research, oncology (1990-1994), Toronto General Hospital, Toronto, Canada; associate professor (1990-1994) and assistant professor (1985-1990), obstetrics and gynecology, immunology, clinical biochemistry, University of Toronto, Toronto, Canada.
Education
PhD, biochemistry (1984), MD (1977), and BMedSci (1975), University of Alberta, Edmonton, Canada.
Postdoctoral Training
Research fellow, immunology, The Hospital for Sick Children (1982-1985); resident, obstetrics and gynecology (1980-1982), graduate studies, biochemistry (1978-1984), honorary resident, obstetrics and gynecology (1978-1980), and straight intern, obstetrics and gynecology (1977-1978), University of Alberta, Alberta, Canada; research fellow, obstetrics and gynecology (1976-1978), Flinders Medical Center, Adelaide, Australia.
Selected AACR Service, Honors, and Awards
Recipient, AACR-AstraZeneca Career Development Award for Physician-Scientists in Honor of José Baselga, Scientific Review Committee (2023-2025); recipient, AACR Women’s Cancer Initiative Ad Hoc Committee (2022-2025); member, AACR-AstraZeneca Career Development Award for Physician-Scientists, in Honor of José Baselga, Scientific Review Committee (2021-2023); recipient, AACR Team Science Award (2021); member, Publications Committee (2020-2023, 2017-2020); member, Board of Directors (2017-2020); member, AACR Project GENIE Steering Committee (2016-2018); member, AACR NextGen Grants for Transformative Cancer Research Review Committee (2016-2018); member, Exhibits Committee (2016-2019); cochair, AACR/Rivkin Center for Ovarian Cancer 11th Biennial Ovarian Cancer Research Symposium (2016); cochair (2016) and member (2015), Clinical Research and Experimental Therapeutics Awards Committee; chair, Precision Medicine Series, “Drug Sensitivity and Resistance: Improving Cancer Therapy” (2014); member, Annual Meeting Education Committee (2013); member, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Scientific Committee (2012-2016, 2009, 2007, 2001); member, Clinical and Translational Cancer Research Grants Scientific Committee (2013-2015); member, Landon-AACR Innovator Award for Research in Personalized Cancer Medicine Scientific Review Committee (2012-2014); scientific editor, Cancer Discovery (2011-present); cochair, AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development (2008, 2010); senior editor, Molecular Cancer Research (2007-2011).
Selected Non-AACR Service, Honors, and Awards
Recipient, Society of Gynecological Oncology Innovation Award (2021); member, NCI DP2 Early Career Development Award Committee (2020-present); chair, NCI Multidisciplinary Approaches to Understand Cancer Treatment Resistance (2020); chair, external advisory board, Ontario Institute for Cancer Research (2020); recipient, Harvey Baker Memorial Lectureship (2019); recipient, Finneran Family Prize for Excellence in Translational Research (2016); elected member, Association of American Physicians (AAP) (2015); recipient, Laura Ziskin Award, Stand Up To Cancer/AACR (2014); recipient, Susan G. Komen Brinker Award for Excellence in Science (2013); elected fellow, American Association for the Advancement of Science (AAAS) (2012); recipient, Waun Ki Hong Award for Excellence in Team Science, The University of Texas MD Anderson Cancer Center (2009); recipient, Peter Steck Memorial Award, Brain Tumor Foundation (2008); recipient, Rafael Research Alumni Association Professorship at Rambam, Israel (2008); recipient, Inaugural Waun Ki Hong Award for Mentorship, The University of Texas MD Anderson Cancer Center (2006).